Accurate Biogene
Accurate Biogene is a comprehensive, easy to use life science search engine for life scientists, researchers, graduate students, and health professionals.
|
Orthogate  News curasan AG receives license for Osbone®
|
curasan AG receives license for Osbone® |
|
|
|
|
curasan AG has
received CE certification and, therefore, marketing authorization
throughout Europe of the synthetic bone replacement material Osbone®
Kleinostheim, Germany, 10th
December 2009 - curasan AG, which is listed in General Standard of the
German Stock Exchange (ISIN: DE 000 549 453 8), has received CE
certification and, therefore, marketing authorization throughout Europe
of the synthetic bone replacement material Osbone®. Osbone®
is suitable for utilisation in general bone surgery, particularly in
implantology and oral and maxillofacial surgery associated with jawbone
atrophy. The
product consists of an open-celled, porous and biocompatible
hydroxylapatite ceramic. It is extremely well tolerated by tissue, is
not absorbable and is firmer than standard bone substance, which
complies with the wishes of many physicians and dentists. Its spongy,
interconnected cells match the natural bone trabecula structure, thereby allow integration into the surrounding viable bone. In contrast to materials with biological origins, Osbone® is not associated with any risks relating to potential infections or the development of allergies. Hans Dieter Rössler, CEO of curasan AG, explains the advantage of the new product: "Just like the absorbable Cerasorb®, which has already been launched, Osbone®
is 100% synthetic and offers practitioners as well as patients the
guarantee that the material itself will not result in any adverse
effects."
The market launch is planned for March 2010.
Background information about curasan AG:Exchange
listed curasan AG (ISIN: DE 000 549 453 8) is one of the leading firms
in the field of regenerative medicine especially in bone and tissue
regeneration. In addition to the synthetic Cerasorb® bone
substitution and regeneration material, the company has developed a
future-oriented product pipeline. The goal during the next few years is
to have further medical products ready for market rollout via
well-positioned contractual partners in various market segments.
Press Contact: curasan AGAndrea WeidnerTel. +49 (0)6027 40 900-51Fax +49 (0)6027 40 900-39andrea.weidner@curasan.dewww.curasan.de fr financial relations gmbhJörn GleisnerTel. +49 (0)69 95 90 83 20Fax +49 (0)69 95 90 83 99j.gleisner@finanical-relations.de
|
|
Last Updated ( Sunday, 27 December 2009 )
|
|
Submit Community NewsIf you have some orthopedic news that you would like to share with the Orthogate community, please register/login and submit your news, event, article, announcement or review from the Submit Content menu in your Members Area. Join now .
|
We subscribe to the HONcode principles. Verify here